1. Aabo K (1987) Prostate cancer: evaluation of response to treatment, response criteria, and need for standardization of the reporting of results. Eur J Cancer Clin Oncol 23: 231–236.
2. Adelstein DJ (1995) Palliative chemotherapy for non-small cell lung cancer. Semin Oncol 22 (suppl 3): 35–39.
3. Bearman SI, Shpall EJ, Jones RB et al (1996) High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer. Semin Oncol 23 (suppl 2): 60–67.
4. Bissery MC, Nohynek G, Sanderink GJ (1995) Docetaxel (taxotere Rm): a review of preclinical experience. Part 1: preclinical experience. Anticancer Drugs 6: 339–368.
5. Bjarson G, Hrushesky WJ, Diasio R et al. (1994) Flat versus circadian modified 14 day infusion of FUDR for advanced renal cell cancer (RCC): a phase-III study. Proc Am Soc Clin Oncol 1: 718 (Abstract 233).